Related Experiment Videos
Serum myoglobin levels in patients with ischemic myocardial insult
Insights
Serum myoglobin is a reliable indicator of myocardial necrosis, detecting small acute myocardial infarctions. Elevated levels in chest pain patients help identify those at higher risk for complications like heart failure.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Diagnostics
Background:
- Chest pain is a common presenting symptom requiring accurate diagnosis of cardiac injury.
- Early detection of acute myocardial infarction (AMI) is crucial for patient outcomes.
- Existing biomarkers may not fully capture the spectrum of ischemic cardiac injury.
Purpose of the Study:
- To evaluate serum myoglobin as a diagnostic marker for ischemic cardiac injury.
- To compare serum myoglobin levels with clinical presentation and other cardiac markers.
- To identify potential prognostic implications of serum myoglobin in chest pain patients.
Main Methods:
- Serum myoglobin levels were measured in 178 patients admitted for chest pain.
- Levels were correlated with clinical status, electrocardiographic changes, and serum creatine kinase (CK).
- Patients were categorized based on World Health Organization (WHO) criteria for AMI and myoglobin levels.
Main Results:
- Elevated serum myoglobin was found in all AMI patients and 50% of acute coronary insufficiency (ACI) cases.
- ACI patients with elevated myoglobin (Group 1) had higher CK than those with normal myoglobin (Group 2).
- Group 1 patients experienced more heart failure and AMI complications than Group 2.
Conclusions:
- Serum myoglobin is a sensitive marker for myocardial necrosis.
- It can identify a subgroup of ACI patients with elevated myoglobin, indicating subclinical myocardial damage.
- Myoglobin elevation correlates with infarct size and has prognostic value in detecting small AMIs.
Abstract:
Serum myoglobin levels were studied in 178 consecutive patients admitted for chest pain due to ischemic cardiac injury. Serum myoglobin level was compared with the clinical condition, electrocardiographic changes, and serum creatine kinase levels. Elevated serum myoglobin concentration was present in all patients with acute myocardial infarction, as defined by World Health Organization, Geneva, criteria, and, in addition, in about 50% of patients with so-called acute coronary insufficiency. On this basis we could define two different groups of patients with acute coronary insufficiency: cases exhibiting elevated serum myoglobin levels (group 1) and those with normal levels (group 2). In group 1 although creatine kinase levels were in the normal range, they were significantly higher than in group 2. Four patients from group 1 developed heart failure and another a typical acute myocardial infarction during hospitalization, whereas no patients of group 2 had such complications. In patients with acute myocardial infarction, the elevation of serum myoglobin preceded that of creatine kinase in most cases. Myoglobin release appears to be related to infarct size, the highest levels were found in extensive myocardial infarction and less marked elevations in cases of subendocardial infarction and in half of the cases with acute coronary insufficiency. It is proposed that serum myoglobin is a reliable measure of myocardial necrosis and serves to detect a hitherto undefined population of small-size acute myocardial infarction, with its attendant clinical and prognostic implications.